Close Menu


Results of the randomized Phase III BROCADE trial, recently published in The Lancet Oncology, suggested a benefit of veliparib combined with platinum-based chemotherapy.

With studies showing BRCA-mutated patients have a greater magnitude of benefit, oncologists grapple with complex treatment decisions in BRCA mutation-free cases.

Findings from three Phase III clinical trials suggest that PARP inhibitors may prolong disease-free survival in some advanced ovarian cancer patients without BRCA1/2 mutations.